Show results for
Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Stem Cell Transplants Equipment Supplied In Usa
22 equipment items found
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-100, our DeltEx Allo, is an allogeneic product candidate, initially developed for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation (HSCT). This is the first clinical trial of an expanded and activated allogeneic gamma delta T cell ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-155 is an investigational, oral, rationally designed, fermented microbiome therapeutic designed to reduce the incidence of gastrointestinal infections, bacteremia, and graft versus host disease (GvHD) in immunocompromised patients, including patients receiving allogeneic hematopoietic stem cell transplantation ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and ...
by:Gain Therapeutics, Inc. based inBethesda, MARYLAND (USA)
These mutations cause the misfolding and dysfunction of IDUA, which leads to the toxic buildup of large sugars in the bone, cartilage, cornea, heart and central nervous system (CNS). There is currently no cure for these patients; however, enzyme replacement therapy and hematopoietic stem cell transplant are used to manage the non-CNS symptoms. ...
Manufactured by:ELITechGroup based inPuteaux, FRANCE
Epstein-Barr Virus (EBV) is a widespread herpesvirus, generally asymptomatic or sometimes responsible for mild infection like mononucleosis. After solid organ or hematopoietic stem cell transplant, EBV reactivation is a common cause of malignant transformation, called Post-Transplant Lymphoproliferative Disorder ...
by:Gain Therapeutics, Inc. based inBethesda, MARYLAND (USA)
Very limited and investigational symptomatic treatment options include substrate reduction therapy, enzyme replacement therapy, bone marrow transplantation, stem cell transplantation and gene therapy to address non-CNS symptoms. Gain is developing allosteric regulators that are designed to decrease toxic substrate accumulation in ...
by:Gain Therapeutics, Inc. based inBethesda, MARYLAND (USA)
Very limited and investigational symptomatic treatment options include substrate reduction therapy, enzyme replacement therapy, bone marrow transplantation, stem cell transplantation and gene therapy to address non-CNS symptoms. Gain is developing allosteric regulators that are designed to decrease toxic substrate accumulation in ...
Manufactured by:ProImmune Ltd. based inOxford, UNITED KINGDOM
ProMix™ Peptide Pools purified immunodominant epitope peptide pools for precise monitoring of functional T cell ...
Manufactured by:Verax Biomedical, Incorporated based inMarlborough, MASSACHUSETTS (USA)
Stem cells, activated leukocytes and other cellular therapies are another area of obvious applicability for PGD technology as these cells are grown in media that also support bacterial proliferation. As with platelets and red blood cells, current techniques for the detection of contaminating bacteria before ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
VOR33 is our lead eHSC product candidate designed to replace the standard of care in transplant settings. Once the VOR33 cells have engrafted, we believe that patients can be treated with anti-CD33 therapies, such as Mylotarg or VCAR33, with limited on-target toxicity, leading to durable anti-tumor activity and potential cures. In preclinical studies, we have observed that the removal of CD33 ...
Manufactured by:Universal Cells Inc. based inSeattle, WASHINGTON (USA)
Realizing the potential of pluripotent stem cells requires that the therapeutic cells derived from PSCs be accepted by patients. PSC-derived cells that have not been engineered to avoid allogeneic rejection will be eliminated soon after transplantation unless they are HLA-matched to their recipients, delivered to ...
Manufactured by:U.S. Stem Cell, Inc. (USRM) based inSunrise, FLORIDA (USA)
MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell. The myoblast cells to be injected are gene-modified prior to injection by an adenovirus vector so that they will release extra quantities of stromal derived factor – 1 or SDF-1 protein. Following injury which results in inadequate blood flow to the heart, such as ...
Manufactured by:ELITechGroup based inPuteaux, FRANCE
Aspergillosis is the most common cause of fungal infection among stem cell and solid organ transplant recipients, resulting in high mortality if untreated. Patients with weakened immune system and lung diseases are at higher risk of developing severe outcomes. Early detection and quantification of Aspergillus with molecular methods is crucial to ...
by:Osel Inc. based inMountain View, CALIFORNIA (USA)
CBM588 is an orally-administered Clostridium butyricum strain with a long history of clinical use and safety in all age groups in Japan. In Japan, CBM588 has primarily been used to treat infectious and noninfectious diarrheal disorders associated with dysbiosis of the human gastrointestinal microbiome. CBM588 inhibits certain enteric pathogens and supports colonic homeostasis by producing butyric ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas ...
Manufactured by:Ocugen, Inc. based inMalvern, PENNSYLVANIA (USA)
OCU400 (AAV-NR2E3) is a novel gene therapy product candidate with the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases (“IRDs”). It consists of a functional copy of a nuclear hormone receptor (“NHR”) gene, NR2E3, delivered to target cells in the retina using an adeno-associated ...
Manufactured by:ACROBiosystems based inNewark, DELAWARE (USA)
Interleukin 7 is also known as IL7, IL-7, and is a hematopoietic growth factor secreted by stromal cells in the red marrow and thymus. It is also produced by keratinocytes, dendritic cells, hepatocytes, neurons, and epithelial cells, but is not produced by lymphocytes. IL-7 stimulates the differentiation of multipotent (pluripotent) hematopoietic stem cells into lymphoid progenitor cells, It also ...
Manufactured by:Targazyme, Inc. based inCarlsbad, CALIFORNIA (USA)
TZ 102, like all of TargaZyme’s therapeutics, is an off-the-shelf product for point-of-care use. It’s made of two (2) components, fucosyltransferase VII enzyme and GDP ...
Manufactured by:Forge Biologics, Inc. based inGrove City, OHIO (USA)
Krabbe disease is a devastating neurodegenerative disease affecting about 1 -2.5 in 100,000 people in the U.S. and is inherited in an autosomal recessive manner. Krabbe disease is caused by loss-of-function mutations in the galactosylceramidase (GALC) gene, a lysosomal enzyme responsible for the breakdown of certain types of lipids such as psychosine. Without functional GALC, psychosine ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Mocravimod is an oral activity amphematoshenol-1-1-phosphate receptor (S1PR) regulator, which can block the required signal from lymph organs to prevent the migration of effect cells from migrating to non-lymph hematopoietic tissue. Mocravimod can be used for cancer ...